Development of a positive-readout mouse model of siRNA pharmacodynamics

Molecular Therapy Nucleic Acids

Volumn 2, Issue NOV, 2013, Pages e133-

  Stevenson, Mark ^a   Carlisle, Robert ^b   Davies, Ben ^c   Preece, Chris ^c   Hammett, Michelle ^c   Liu, Wei Li ^a   Fisher, Kerry David ^a   Ryan, Amy ^d   Scrable, Heidi ^e   Seymour, Leonard William ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Champlain Valley Physicians Hospital   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

Lac operon; Lac repressor; Transgenic reporter mouse

Indexed keywords

DRINKING WATER; ISOPROPYL THIOGALACTOSIDE; LAC REPRESSOR; LIPOFECTAMINE; LUCIFERASE; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CONTROLLED STUDY; ELECTROPORATION; ESCHERICHIA COLI; FEMALE; HEART; KIDNEY; LACTOSE OPERON; LIVER; LUNG; MATING; MOUSE; MUSCLE; NONHUMAN; OVARY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; REPORTER GENE; RNA INTERFERENCE; SPLEEN; TRANSIENT TRANSFECTION; UTERINE TUBE; WESTERN BLOTTING; WHOLE BODY IMAGING;

EID: 84893829026     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.63     Document Type: Article

References (38)

1. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811. (Pubitemid 28099681)
2. Tuschl, T, Zamore, PD, Lehmann, R, Bartel, DP and Sharp, PA (1999). Targeted mRNA degradation by double-stranded RNA in vitro. Genes Dev 13: 3191-3197. (Pubitemid 30030441)
3. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498. (Pubitemid 32494397)
4. Rettig, GR and Behlke, MA (2012). Progress toward in vivo use of siRNAs-II. Mol Ther 20: 483-512.
5. Burnett, JC, Rossi, JJ and Tiemann, K (2011). Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6: 1130-1146.
6. Singerman, L (2009). Combination therapy using the small interfering RNA bevasiranib. Retina (Philadelphia, Pa) 29(6 suppl.): S49-S50.
7. Bitko, V, Musiyenko, A, Shulyayeva, O and Barik, S (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11: 50-55. (Pubitemid 40215837)
8. Fulton, A, Peters, ST, Perkins, GA, Jarosinski, KW, Damiani, A, Brosnahan, M et al. (2009). Effective treatment of respiratory alphaherpesvirus infection using RNA interference. PLoS ONE 4: e4118.
9. Li, BJ, Tang, Q, Cheng, D, Qin, C, Xie, FY, Wei, Q et al. (2005). Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 11: 944-951. (Pubitemid 41294439)
10. Bumcrot, D, Manoharan, M, Koteliansky, V and Sah, DW (2006). RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2: 711-719. (Pubitemid 44764213)
11. Lewis, DL and Wolff, JA (2005). Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Meth Enzymol 392: 336-350. (Pubitemid 40092524)
12. Lewis, DL and Wolff, JA (2007). Systemic siRNA delivery via hydrodynamic intravascular injection. Adv Drug Deliv Rev 59: 115-123. (Pubitemid 46770902)
13. Morrissey, DV, Lockridge, JA, Shaw, L, Blanchard, K, Jensen, K, Breen, W et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007. (Pubitemid 41114035)
14. Santel, A, Aleku, M, Röder, N, Möpert, K, Durieux, B, Janke, O et al. (2010). Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 16: 5469-5480.
15. Polach, KJ, Matar, M, Rice, J, Slobodkin, G, Sparks, J, Congo, R et al. (2012). Delivery of siRNA to the mouse lung via a functionalized lipopolyamine. Mol Ther 20: 91-100.
16. Malek, A, Merkel, O, Fink, L, Czubayko, F, Kissel, T and Aigner, A (2009). In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 236: 97-108.
17. Günther, M, Lipka, J, Malek, A, Gutsch, D, Kreyling, W and Aigner, A (2011). Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm 77: 438-449.
18. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178. (Pubitemid 39545841)
19. Song, E, Zhu, P, Lee, SK, Chowdhury, D, Kussman, S, Dykxhoorn, DM et al. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717. (Pubitemid 41716361)
20. Moschos, SA, Jones, SW, Perry, MM, Williams, AE, Erjefalt, JS, Turner, JJ et al. (2007). Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 18: 1450-1459. (Pubitemid 47464052)
21. Rosi, NL, Giljohann, DA, Thaxton, CS, Lytton-Jean, AK, Han, MS and Mirkin, CA (2006). Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312: 1027-1030.
22. Braun, GB, Pallaoro, A, Wu, G, Missirlis, D, Zasadzinski, JA, Tirrell, M et al. (2009). Laser-Activated Gene Silencing via Gold Nanoshell-siRNA Conjugates. ACS Nano 3: 2007-2015.
23. Dunne, J, Drescher, B, Riehle, H, Hadwiger, P, Young, BD, Krauter, J et al. (2003). The apparent uptake of fluorescently labeled siRNAs by electroporated cells depends on the fluorochrome. Oligonucleotides 13: 375-380. (Pubitemid 38404822)
24. Larson, SD, Jackson, LN, Chen, LA, Rychahou, PG and Evers, BM (2007). Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery 142: 262-269. (Pubitemid 47198678)
25. van de Water, FM, Boerman, OC, Wouterse, AC, Peters, JG, Russel, FG and Masereeuw, R (2006). Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 34: 1393-1397. (Pubitemid 44079881)
26. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
27. Medarova, Z, Pham, W, Farrar, C, Petkova, V and Moore, A (2007). In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 13: 372-377. (Pubitemid 46376679)
28. Palliser, D, Chowdhury, D, Wang, QY, Lee, SJ, Bronson, RT, Knipe, DM et al. (2006). An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439: 89-94. (Pubitemid 43053634)
29. Svensson, RU, Shey, MR, Ballas, ZK, Dorkin, JR, Goldberg, M, Akinc, A et al. (2008). Assessing siRNA pharmacodynamics in a luciferase-expressing mouse. Mol Ther 16: 1995-2001.
30. Liu, WL, Owen, DP, Fisher, KD, Seymour, LW and Stevenson, M (2009). Establishment of a positive-readout reporter system for siRNAs. J RNAi Gene Silencing 5: 331-338.
31. Jacob, F and Monod, J (1961). Genetic regulatory mechanisms in the synthesis of proteins. J Mol Biol 3: 318-356.
32. Scrable, H and Stambrook, PJ (1997). Activation of the lac repressor in the transgenic mouse. Genetics 147: 297-304. (Pubitemid 27385557)
33. Cronin, CA, Gluba, W and Scrable, H (2001). The lac operator-repressor system is functional in the mouse. Genes Dev 15: 1506-1517. (Pubitemid 32552530)
34. Ryan, A and Scrable, H (2004). Visualization of the dynamics of gene expression in the living mouse. Mol Imaging 3: 33-42.
35. Farr, A and Roman, A (1992). A pitfall of using a second plasmid to determine transfection efficiency. Nucleic Acids Res 20: 920.
36. Deans, TL, Cantor, CR and Collins, JJ (2007). A tunable genetic switch based on RNAi and repressor proteins for regulating gene expression in mammalian cells. Cell 130: 363-372. (Pubitemid 47081136)
37. Lin, X, Li, L, Wang, R, Wilcox, D, Zhao, X, Song, J et al. (2011). A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. RNA 17: 603-612.
38. Kleinman, ME, Yamada, K, Takeda, A, Chandrasekaran, V, Nozaki, M, Baffi, JZ et al. (2008). Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452: 591-597. (Pubitemid 351483358)